| Parkinson Disease
Apokyn vs Xadago
Side-by-side clinical, coverage, and cost comparison for parkinson disease.Deep comparison between: Apokyn vs Xadago with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsXadago has a higher rate of injection site reactions vs Apokyn based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Xadago but not Apokyn, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Apokyn
Xadago
At A Glance
SC injection
As needed (PRN)
Dopamine agonist (non-ergoline)
Oral
Daily
MAO-B inhibitor
Indications
- Parkinson Disease
- Parkinson Disease
Dosing
Parkinson Disease Starting dose 0.1 mL (1 mg) to 0.2 mL (2 mg) SC as needed for "off" episodes; titrate in 0.1 mL (1 mg) increments every few days; maximum 0.6 mL (6 mg) per dose; doses must be separated by at least 2 hours. Reduce starting dose to 0.1 mL (1 mg) in mild or moderate renal impairment.
Parkinson Disease Start with 50 mg orally once daily; after two weeks, may increase to 100 mg once daily based on individual need and tolerability; maximum 50 mg once daily in moderate hepatic impairment (Child-Pugh B); contraindicated in severe hepatic impairment (Child-Pugh C).
Contraindications
- Concomitant use of 5HT3 antagonists including antiemetics (ondansetron, granisetron, dolasetron, palonosetron) and alosetron
- Hypersensitivity or allergic reaction to apomorphine or any excipient including sodium metabisulfite
- Concomitant use of other MAOIs or potent monoamine oxidase inhibitors, including linezolid
- Concomitant use of opioid drugs (meperidine and its derivatives, methadone, propoxyphene, or tramadol), SNRIs, tricyclic/tetracyclic/triazolopyridine antidepressants, cyclobenzaprine, methylphenidate, amphetamine and their derivatives, or St John's wort
- Concomitant use of dextromethorphan
- History of hypersensitivity to safinamide
- Severe hepatic impairment (Child-Pugh C: 10-15)
Adverse Reactions
Most common (>=10% above placebo) Yawning, dyskinesias, drowsiness/somnolence, nausea/vomiting, dizziness/postural hypotension, rhinorrhea, hallucination/confusion, edema/swelling of extremities
Serious Nausea and vomiting, syncope/hypotension/orthostatic hypotension, falls, hallucinations/psychotic-like behavior, dyskinesias, hemolytic anemia, impulse control/compulsive behaviors, coronary events, QTc prolongation, withdrawal-emergent hyperpyrexia and confusion, hypersensitivity, fibrotic complications, priapism
Postmarketing Hemolytic anemia
Most common (>=2%) Dyskinesia, fall, nausea, insomnia, orthostatic hypotension, anxiety, cough, dyspepsia
Serious Hypertension, serotonin syndrome, falling asleep during activities of daily living, dyskinesia, hallucinations/psychotic behavior, impulse control/compulsive behaviors, withdrawal-emergent hyperpyrexia and confusion, retinal pathology
Postmarketing Hypersensitivity (swelling of tongue and gingiva, dyspnea, skin rash), headache
Pharmacology
APOKYN is a non-ergoline dopamine agonist with high binding affinity for the dopamine D4 receptor and moderate affinity for D2, D3, D5, and adrenergic receptors; its therapeutic effect in Parkinson's disease is believed to result from stimulation of post-synaptic dopamine D2-type receptors within the caudate-putamen.
MAO-B inhibitor; safinamide selectively inhibits MAO-B with more than 1000-fold selectivity over MAO-A, blocking catabolism of dopamine and thereby increasing dopamine levels and dopaminergic activity in the brain.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Apokyn
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (9/12)
Xadago
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Apokyn
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (3/8)
Xadago
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Apokyn
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Xadago
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableApokyn Patient Assistance Program
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Xadago.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ApokynView full Apokyn profile
XadagoView full Xadago profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.